These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 32189093)
1. A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. Cleary JM; Calvo E; Moreno V; Juric D; Shapiro GI; Vanderwal CA; Hu B; Gifford M; Barch D; Roberts-Rapp L; Ansell PJ; Xiong H; Ocampo C; Tolcher AW Invest New Drugs; 2020 Oct; 38(5):1483-1494. PubMed ID: 32189093 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor. Goss GD; Vokes EE; Gordon MS; Gandhi L; Papadopoulos KP; Rasco DW; Fischer JS; Chu KL; Ames WW; Mittapalli RK; Lee HJ; Zeng J; Roberts-Rapp LA; Loberg LI; Ansell PJ; Reilly EB; Ocampo CJ; Holen KD; Tolcher AW Cancer; 2018 May; 124(10):2174-2183. PubMed ID: 29533458 [TBL] [Abstract][Full Text] [Related]
3. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090 [TBL] [Abstract][Full Text] [Related]
4. Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models. Jain S; Griffith JI; Porath KA; Rathi S; Le J; Pasa TI; Decker PA; Gupta SK; Hu Z; Carlson BL; Bakken K; Burgenske DM; Feldsien TM; Lefebvre DR; Vaubel RA; Eckel-Passow JE; Reilly EB; Elmquist WF; Sarkaria JN Clin Cancer Res; 2024 Aug; 30(15):3287-3297. PubMed ID: 38743766 [TBL] [Abstract][Full Text] [Related]
5. A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. Lemech C; Woodward N; Chan N; Mortimer J; Naumovski L; Nuthalapati S; Tong B; Jiang F; Ansell P; Ratajczak CK; Sachdev J Invest New Drugs; 2020 Dec; 38(6):1815-1825. PubMed ID: 32524319 [TBL] [Abstract][Full Text] [Related]
6. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate. Anderson MG; Falls HD; Mitten MJ; Oleksijew A; Vaidya KS; Boghaert ER; Gao W; Palma JP; Cao D; Chia PL; John T; Gan HK; Scott AM; Reilly EB Mol Cancer Ther; 2020 Oct; 19(10):2117-2125. PubMed ID: 32847977 [TBL] [Abstract][Full Text] [Related]
7. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518 [TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors. Fujiwara Y; Kenmotsu H; Yamamoto N; Shimizu T; Yonemori K; Ocampo C; Parikh A; Okubo S; Fukasawa K; Murakami H Cancer Med; 2021 Apr; 10(7):2350-2358. PubMed ID: 33675179 [TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors. Tang M; Garg A; Bonate PL; Rosenberg JE; Matsangou M; Kadokura T; Yamada A; Choules M; Pavese J; Nagata M; Tenmizu D; Koibuchi A; Heo N; Wang L; Wojtkowski T; Hanley WD; Poondru S Clin Pharmacokinet; 2024 Apr; 63(4):423-438. PubMed ID: 38609704 [TBL] [Abstract][Full Text] [Related]
10. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Advani RH; Lebovic D; Chen A; Brunvand M; Goy A; Chang JE; Hochberg E; Yalamanchili S; Kahn R; Lu D; Agarwal P; Dere RC; Hsieh HJ; Jones S; Chu YW; Cheson BD Clin Cancer Res; 2017 Mar; 23(5):1167-1176. PubMed ID: 27601593 [No Abstract] [Full Text] [Related]
11. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. Paz-Ares LG; Gomez-Roca C; Delord JP; Cervantes A; Markman B; Corral J; Soria JC; Bergé Y; Roda D; Russell-Yarde F; Hollingsworth S; Baselga J; Umana P; Manenti L; Tabernero J J Clin Oncol; 2011 Oct; 29(28):3783-90. PubMed ID: 21900113 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial. Qiu MZ; Zhang Y; Guo Y; Guo W; Nian W; Liao W; Xu Z; Zhang W; Zhao HY; Wei X; Xue L; Tang W; Wu Y; Ren G; Wang L; Xi J; Jin Y; Li H; Hu C; Xu RH JAMA Oncol; 2022 Jul; 8(7):1042-1046. PubMed ID: 35511148 [TBL] [Abstract][Full Text] [Related]
13. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Liu J; Burris H; Wang JS; Barroilhet L; Gutierrez M; Wang Y; Vaze A; Commerford R; Royer-Joo S; Choeurng V; Humke E; Moore K Gynecol Oncol; 2021 Dec; 163(3):473-480. PubMed ID: 34627611 [TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Stathis A; Flinn IW; Madan S; Maddocks K; Freedman A; Weitman S; Zucca E; Munteanu MC; Lia Palomba M Invest New Drugs; 2018 Oct; 36(5):869-876. PubMed ID: 29453628 [TBL] [Abstract][Full Text] [Related]
15. A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer. Kollmannsberger C; Britten CD; Olszanski AJ; Walker JA; Zang W; Willard MD; Radtke DB; Farrington DL; Bell-McGuinn KM; Patnaik A Invest New Drugs; 2021 Dec; 39(6):1613-1623. PubMed ID: 34264412 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR. Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167 [TBL] [Abstract][Full Text] [Related]
17. Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers. Hou MM; Ho CL; Lin HY; Zhu Y; Zhang X Invest New Drugs; 2021 Oct; 39(5):1315-1323. PubMed ID: 33713216 [TBL] [Abstract][Full Text] [Related]
18. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. Gerber DE; Infante JR; Gordon MS; Goldberg SB; Martín M; Felip E; Martinez Garcia M; Schiller JH; Spigel DR; Cordova J; Westcott V; Wang Y; Shames DS; Choi Y; Kahn R; Dere RC; Samineni D; Xu J; Lin K; Wood K; Royer-Joo S; Lemahieu V; Schuth E; Vaze A; Maslyar D; Humke EW; Burris HA Clin Cancer Res; 2020 Jan; 26(2):364-372. PubMed ID: 31540980 [TBL] [Abstract][Full Text] [Related]
19. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. Han TH; Gopal AK; Ramchandren R; Goy A; Chen R; Matous JV; Cooper M; Grove LE; Alley SC; Lynch CM; O'Connor OA J Clin Pharmacol; 2013 Aug; 53(8):866-77. PubMed ID: 23754575 [TBL] [Abstract][Full Text] [Related]
20. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate. Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]